Krystal Biotech Statistics

Total Valuation

Krystal Biotech has a market cap or net worth of $10.97 billion. The enterprise value is $9.97 billion.

Market Cap	10.97B
Enterprise Value	9.97B

Important Dates

The next estimated earnings date is Monday, August 3, 2026, before market open.

Earnings Date	Aug 3, 2026
Ex-Dividend Date	n/a

Share Statistics

Krystal Biotech has 29.48 million shares outstanding. The number of shares has increased by 0.75% in one year.

Current Share Class	29.48M
Shares Outstanding	29.48M
Shares Change (YoY)	+0.75%
Shares Change (QoQ)	+0.85%
Owned by Insiders (%)	10.25%
Owned by Institutions (%)	88.37%
Float	23.42M

Valuation Ratios

The trailing PE ratio is 49.85 and the forward PE ratio is 43.35. Krystal Biotech's PEG ratio is 0.69.

PE Ratio	49.85
Forward PE	43.35
PS Ratio	26.30
Forward PS	n/a
PB Ratio	8.58
P/TBV Ratio	8.60
P/FCF Ratio	46.23
P/OCF Ratio	43.85
PEG Ratio	0.69

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 55.22, with an EV/FCF ratio of 41.98.

EV / Earnings	44.29
EV / Sales	23.88
EV / EBITDA	55.22
EV / EBIT	55.76
EV / FCF	41.98

Financial Position

The company has a current ratio of 9.46, with a Debt / Equity ratio of 0.01.

Current Ratio	9.46
Quick Ratio	8.82
Debt / Equity	0.01
Debt / EBITDA	0.05
Debt / FCF	0.04
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 19.90% and return on invested capital (ROIC) is 41.40%.

Return on Equity (ROE)	19.90%
Return on Assets (ROA)	9.04%
Return on Invested Capital (ROIC)	41.40%
Return on Capital Employed (ROCE)	13.86%
Weighted Average Cost of Capital (WACC)	7.15%
Revenue Per Employee	$1.41M
Profits Per Employee	$762,814
Employee Count	295
Asset Turnover	0.34
Inventory Turnover	0.67

Taxes

Income Tax	-17.71M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +161.23% in the last 52 weeks. The beta is 0.53, so Krystal Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.53
52-Week Price Change	+161.23%
50-Day Moving Average	302.83
200-Day Moving Average	249.32
Relative Strength Index (RSI)	77.18
Average Volume (20 Days)	389,312

Short Selling Information

The latest short interest is 3.14 million, so 10.65% of the outstanding shares have been sold short.

Short Interest	3.14M
Short Previous Month	3.15M
Short % of Shares Out	10.65%
Short % of Float	13.40%
Short Ratio (days to cover)	12.47

Income Statement

In the last 12 months, Krystal Biotech had revenue of $417.30 million and earned $225.03 million in profits. Earnings per share was $7.47.

Revenue	417.30M
Gross Profit	392.96M
Operating Income	178.73M
Pretax Income	207.32M
Net Income	225.03M
EBITDA	180.47M
EBIT	178.73M
Earnings Per Share (EPS)	$7.47

Full Income Statement

Balance Sheet

The company has $823.41 million in cash and $9.11 million in debt, giving a net cash position of $1.01 billion or $34.19 per share.

Cash & Cash Equivalents	823.41M
Total Debt	9.11M
Net Cash	1.01B
Net Cash Per Share	$34.19
Equity (Book Value)	1.28B
Book Value Per Share	43.37
Working Capital	911.94M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $250.28 million and capital expenditures -$12.90 million, giving a free cash flow of $237.38 million.

Operating Cash Flow	250.28M
Capital Expenditures	-12.90M
Depreciation & Amortization	1.74M
Net Borrowing	n/a
Free Cash Flow	237.38M
FCF Per Share	$8.05

Full Cash Flow Statement

Margins

Gross margin is 94.17%, with operating and profit margins of 42.83% and 53.92%.

Gross Margin	94.17%
Operating Margin	42.83%
Pretax Margin	49.68%
Profit Margin	53.92%
EBITDA Margin	43.25%
EBIT Margin	42.83%
FCF Margin	56.88%

Dividends & Yields

Krystal Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.75%
Shareholder Yield	-0.75%
Earnings Yield	2.05%
FCF Yield	2.16%

Analyst Forecast

The average price target for Krystal Biotech is $339.22, which is -8.87% lower than the current price. The consensus rating is "Strong Buy".

Price Target	$339.22
Price Target Difference	-8.87%
Analyst Consensus	Strong Buy
Analyst Count	11
Revenue Growth Forecast (3Y)	31.18%
EPS Growth Forecast (3Y)	26.32%

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Krystal Biotech has an Altman Z-Score of 29.48 and a Piotroski F-Score of 5.

Altman Z-Score	29.48
Piotroski F-Score	5